New cocktail of drugs targets Hard-to-Treat stomach cancer

NCT ID NCT06519591

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This phase 2 trial is testing a combination of four drugs—cadonilimab, LM-302, S-1, and paclitaxel—in 40 people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The drugs are given through a vein and directly into the abdomen to attack the cancer from multiple angles. The main goal is to see if this approach improves survival after one year and shrinks tumors enough to allow surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cadonilimab, LM-302, S-1, and paclitaxel
What this could lead to
If successful, this could offer a new treatment option for people with advanced gastric cancer that has spread to the lining of the abdomen, potentially improving survival and enabling surgery.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and it is not yet known if it works better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA WITH PERITONEAL METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ruijin Hospital Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Huangpu District, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.